This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mejia, A. F.
Right arrow Articles by Christensen, N. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mejia, A. F.
Right arrow Articles by Christensen, N. D.

 Previous Article  |  Next Article 

Journal of Virology, December 2006, p. 12393-12397, Vol. 80, No. 24
0022-538X/06/$08.00+0     doi:10.1128/JVI.01583-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Preclinical Model To Test Human Papillomavirus Virus (HPV) Capsid Vaccines In Vivo Using Infectious HPV/Cottontail Rabbit Papillomavirus Chimeric Papillomavirus Particles{triangledown}

Andres F. Mejia,1,{dagger} Timothy D. Culp,1,{dagger} Nancy M. Cladel,1 Karla K. Balogh,1 Lynn R. Budgeon,1 Christopher B. Buck,3 and Neil D. Christensen1,2*

Gittlen Cancer Research Foundation, Pennsylvania State University College of Medicine, Hershey, Pennsylvania,1 Department of Microbiology and Immunology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania,2 Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland3

Received 24 July 2006/ Accepted 18 September 2006

A human papillomavirus (HPV) vaccine consisting of virus-like particles (VLPs) was recently approved for human use. It is generally assumed that VLP vaccines protect by inducing type-specific neutralizing antibodies. Preclinical animal models cannot be used to test for protection against HPV infections due to species restriction. We developed a model using chimeric HPV capsid/cottontail rabbit papillomavirus (CRPV) genome particles to permit the direct testing of HPV VLP vaccines in rabbits. Animals vaccinated with CRPV, HPV type 16 (HPV-16), or HPV-11 VLPs were challenged with both homologous (CRPV capsid) and chimeric (HPV-16 capsid) particles. Strong type-specific protection was observed, demonstrating the potential application of this approach.

* Corresponding author. Mailing address: Gittlen Cancer Research Foundation, Pennsylvania State University College of Medicine, 500 University Dr., Hershey, PA 17033-2390. Phone: (717) 531-6185. Fax: (717) 531-5634. E-mail: ndc1{at}psu.edu.

{triangledown} Published ahead of print on 27 September 2006.

{dagger} A.F.M. and T.D.C. contributed equally to this study.

Journal of Virology, December 2006, p. 12393-12397, Vol. 80, No. 24
0022-538X/06/$08.00+0     doi:10.1128/JVI.01583-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Ashrafi, G. H., Piuko, K., Burden, F., Yuan, Z., Gault, E. A., Muller, M., Trawford, A., Reid, S. W. J., Nasir, L., Campo, M. S. (2008). Vaccination of sarcoid-bearing donkeys with chimeric virus-like particles of bovine papillomavirus type 1. J. Gen. Virol. 89: 148-157 [Abstract] [Full Text]  
  • Gambhira, R., Karanam, B., Jagu, S., Roberts, J. N., Buck, C. B., Bossis, I., Alphs, H., Culp, T., Christensen, N. D., Roden, R. B. S. (2007). A Protective and Broadly Cross-Neutralizing Epitope of Human Papillomavirus L2. J. Virol. 81: 13927-13931 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»